Introduction Pulmonary endarterectomy (PEA) is the treatment of choice for Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and can be offered to selected patients with Chronic Thromboembolic Disease without pulmonary hypertension (CTED). Our aim was to map the pathway of UK patients referred to the National PEA MDT and their onwards management. 
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2016 were included. Patients were divided into CTEPH/CTED groups and their pathways followed until July 2017. Results Of the 316 referrals to the PEA MDT there were 246 cases of CTEPH, 46 of CTED and 24 with alternate diagnoses. Age range of referrals was 22-88 years (mean 59 years). 51% were male. The majority of CTEPH cases had technically operable disease (n=200, 81%) with 130 proceeding to PEA (65%). 53% of all CTEPH cases were operated on (figure 1). Median time from first MDT discussion to PEA was 230 days with a median surgical waiting list time of 115 days. 11 patients required ongoing targeted therapy post-operatively. Of the 70 individuals with an operable disease distribution who did not proceed to PEA, 34 patients chose to decline surgery and 36 were rejected by the surgical team due to co-morbid conditions (n=28) or limited symptoms (n=8). Two patients with distal CTEPH underwent Balloon Pulmonary Angioplasty (BPA). Remaining patients were medically managed with targeted therapy. Of CTED cases, 28 (61%) had an operable disease distribution with 8 (29%) proceeding to PEA. 17% of total CTED referrals were operated on. Conclusion This patient pathway mapping is the first undertaken for any national CTEPH/CTED cohort. The majority of UK CTEPH cases suitable for PEA are operated on (65%). The duration of time between MDT referral and PEA is reflective of disease complexity and decision-making process. We observe a group of highly selected individuals with Chronic Thromboembolic Disease (CTED) without pulmonary hypertension who undergo PEA after careful consideration of their symptoms and operative risk. Background Identification of patients with left heart disease (LHD) as the cause of pulmonary hypertension is challenging, developing a tool that can identify these patients would reduce unnecessary referral for investigation at specialist centres and may reduce the burden of invasive investigations. The aim was to investigate the capability of computed tomography (CT)-derived metrics for the diagnosis LHD in a cohort of patients with suspected pulmonary hypertension. Methods Patients with suspected pulmonary hypertension who underwent CT and RHC were identified. Derivation and validation cohorts were randomly constructed to derive and test a binary logistic regression model. All image analysis took place on PACS system blinded to patient's cardiac catheter data and diagnosis. CT measurements of the cardiac chambers and vessels were taken. LHD was defined by increased pulmonary arterial wedge pressure (PAWP) 15 mmHg. A second threshold of 18 mmHg defined more advanced LHD. Backward binary logistic regression in a derivation cohort identified a model for predicting Group 2 PH. This model was tested in the validation cohort and compared to individual CT derived variables using receiver operating characteristic curve analysis and chi-square. Results The CT scans were from 66 different centres and 446 patients were identified, derivation cohort (n=235) and validation cohort (n=211). Left atrial area was found to be most significant individual predictor of elevated PAWP, area under curve (AUC) 0.86, p<0.001, the accuracy was higher for identification of PAWP 18, AUC 0.87, p=0.87, p<0.001. Derived regression models did not add diagnostic value AUC in validation cohort 0.87, p<0.001. A limit for enlarged left atrial area was set at 27.5 cm 2 . This had sensitivity 65% and specificity 90% in predicting Group 2 PH using PAWP 18 mmHg as a threshold. Conclusions CT derived left atrial area is a specific predictor of LHD in suspected pulmonary hypertension. Composite models did not increase diagnostic value. Left atrial area on CT may be a useful tool for diagnosing PH-LHD and may reduce unnecessary referrals to specialist PH centres and reduce the number of invasive investigations.
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